325 related articles for article (PubMed ID: 19340607)
1. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
[TBL] [Abstract][Full Text] [Related]
2. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
3. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
8. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
[TBL] [Abstract][Full Text] [Related]
9. Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Van Heetvelde M; Van Bockstal M; Poppe B; Lambein K; Rosseel T; Atanesyan L; Deforce D; Van Den Berghe I; De Leeneer K; Van Dorpe J; Vral A; Claes KBM
Cancer Lett; 2018 Jul; 425():125-133. PubMed ID: 29580810
[TBL] [Abstract][Full Text] [Related]
10. Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.
Rodríguez-Balada M; Roig B; Melé M; Salvat M; Martorell L; Borràs J; Gumà J
Clin Transl Oncol; 2018 Sep; 20(9):1226-1231. PubMed ID: 29404838
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Hilton JL; Geisler JP; Rathe JA; Hattermann-Zogg MA; DeYoung B; Buller RE
J Natl Cancer Inst; 2002 Sep; 94(18):1396-406. PubMed ID: 12237285
[TBL] [Abstract][Full Text] [Related]
12. Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hit.
Meric-Bernstam F
Ann Surg Oncol; 2007 Sep; 14(9):2428-9. PubMed ID: 17406948
[No Abstract] [Full Text] [Related]
13. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Johannsdottir HK; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Johannsson OT; Heikkilä P; Egilsson V; Olsson H; Borg A; Nevanlinna H; Barkardottir RB
Anticancer Res; 2004; 24(5A):2681-7. PubMed ID: 15521105
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Johannsdottir HK; Jonsson G; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Heikkila P; Egilsson V; Olsson H; Johannsson OT; Nevanlinna H; Borg A; Barkardottir RB
Int J Cancer; 2006 Sep; 119(5):1052-60. PubMed ID: 16570289
[TBL] [Abstract][Full Text] [Related]
15. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
[TBL] [Abstract][Full Text] [Related]
16. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
[TBL] [Abstract][Full Text] [Related]
17. Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.
Locke I; Kote-Jarai Z; Fackler MJ; Bancroft E; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
Breast Cancer Res; 2007; 9(1):R20. PubMed ID: 17324252
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls.
Locke I; Kote-Jarai Z; Bancroft E; Bullock S; Jugurnauth S; Osin P; Nerurkar A; Izatt L; Pichert G; Gui GP; Eeles RA
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1399-402. PubMed ID: 16835343
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Cancer-Specific
Schouten PC; Richters L; Vis DJ; Kommoss S; van Dijk E; Ernst C; Kluin RJC; Marmé F; Lips EH; Schmidt S; Scheerman E; Prieske K; van Deurzen CHM; Burges A; Ewing-Graham PC; Dietrich D; Jager A; de Gregorio N; Hauke J; du Bois A; Nederlof PM; Wessels LF; Hahnen E; Harter P; Linn SC; Schmutzler RK
Clin Cancer Res; 2021 Dec; 27(23):6559-6569. PubMed ID: 34593530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]